Form 4: Teva Pharmaceutical Executive Mark Sabag Reports Sale of Ordinary Shares

Mark Sabag, Executive Vice President at Teva Pharmaceutical Industries, reported the sale of 337,915 ordinary shares at an average price of $18.0439.

Summary

• Mark Sabag, an Executive Vice President at Teva Pharmaceutical Industries, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the sale of 337,915 ordinary shares on May 8, 2025.
• The shares were sold at a weighted average price of $18.0439, with individual transactions ranging from $17.865 to $18.265.
• Following the reported transaction, the reporting person still owns 150,996 shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as it is a standard SEC filing reporting a transaction. The sale itself doesn't necessarily indicate a positive or negative outlook.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry and subject to SEC regulations.

Stakeholder Impact

• The sale of shares by an executive could be perceived differently by stakeholders; some may see it as a lack of confidence, while others may view it as a personal financial decision.

Key Dates

Keywords

Form 4, Teva Pharmaceutical Industries, Mark Sabag, Ordinary Shares, Beneficial Ownership, SEC Filing